4568.T
$2961.00
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.
Recent News
Person Gulf War Drums Unnerve Asian Stock Markets
Asian stock markets retreated Monday after US President Donald Trump issued a 48-hour ultimatum to I
Daiichi Sankyo Deepens Biologics Push As ENHERTU Faces FDA Decision
Daiichi Sankyo (TSE:4568) entered a research collaboration with Voro Therapeutics to advance next generation antibody drug conjugates. The company also partnered with Leveragen to expand in vivo antibody discovery capabilities in biologics. ENHERTU, developed with AstraZeneca, was accepted for U.S. FDA Priority Review for certain breast cancer patients following phase 3 data and global filings. Daiichi Sankyo, a major Japanese pharmaceutical group, is leaning further into biologics and...
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness?
Investors may be wondering whether Daiichi Sankyo Company is attractively priced right now, or if the market is rightly cautious about its shares. The stock last closed at ¥2,965, with a 3.9% move over the past 7 days, a 0.3% change over 30 days, and returns of a 16.0% decline year to date and a 15.8% decline over the past year, along with a 33.9% decline over 3 years and a 0.3% decline over 5 years. Recent news coverage has focused on Daiichi Sankyo Company within the broader...
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp
AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price target on AstraZeneca PLC (NASDAQ:AZN) to 16,000 GBp from 15,500 GBp on March 10, reiterating a Buy rating on the shares and telling investors that it is updating its model after the company’s fiscal 2025 […]
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment
AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo secured Priority Review in the US for Enhertu, their candidate drug for patients with HER2-positive breast cancer. The priority review comes on the heels of the Food and Drug Administration granting Enhertu Breakthrough Therapy Designation, […]